New biomarkers: added clinical value explained Can biomarkers improve clinical decisions?
|
|
- Conrad West
- 5 years ago
- Views:
Transcription
1 New biomarkers: added clinical value explained Can biomarkers improve clinical decisions? Alex Lefevre UZ Leuven 30/11/2012
2 Agenda Introduction Sensitivity Specificity - ROC Biomarkers with added medical value: IL-6 Biomarkers with added medical value: S100 Biomarkers with added medical value: TnT hs Biomarkers with added medical value: NT-proBNP Biomarkers with added medical value: Cystatin C Conclusion
3 Agenda Introduction Sensitivity Specificity - ROC Biomarkers with added medical value: IL-6 Biomarkers with added medical value: S100 Biomarkers with added medical value: TnT hs Biomarkers with added medical value: NT-proBNP Biomarkers with added medical value: Cystatin C Conclusion
4
5 Status 2010
6 Biomarkers: an ongoing evolution
7 The value of diagnostics 1 Costs vs. decision-making Hospital costs Healthcare decision-making Diagnostics While diagnostics comprise less than 5% of hospital costs and about 1,6% of all medical care costs, their findings influence as much as 60% - 70% of healthcare decision-making 1 Source: The Value of diagnostics July 2005 Sept 2009, The Lewing Group
8 Definition of Biomarker Biological Marker (Biomarker): A characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. Biomarkers Definitions Working Group, Clin. Pharmacol. Ther2001; 69, Purpose: Biomarkers are used in clinical practice to identify risk for disease, diagnose disease and its severity, guide intervention strategies, and monitor patient responses to therapy. When used in a clinical research setting, biomarkers may predict whether a drug or other intervention is safe and effective in a shorter time and at lower cost than clinical outcomes studies. CA Altar, ClinPharmacolTher2008; 83:
9 Characteristics of an ideal biomarker Safe to measure Easy to measure Low cost to measure Cost of follow-up tests is relatively low Proven treatment to modify biomarker exists Biomarker modification proven to protect against disease/outcome Consistent across genders and ethnic groups
10 Example : Point-of-care testing in Neonatology Saving time, money and blood Results on the spot Up to 50 % less transfusions Simplification blood collection : capillary blood
11 Example : NT-ProBNP Prognostic value in chronic heart failure Reduce length of stay in hospital Less re-hospitalisations
12 Agenda Introduction Sensitivity Specificity - ROC Biomarkers with added medical value: IL-6 Biomarkers with added medical value: S100 Biomarkers with added medical value: TnT hs Biomarkers with added medical value: NT-proBNP Biomarkers with added medical value: Cystatin C Conclusion
13 What about new diagnostic tests?
14 The sensible use of biomarkers in clinical practice Healthy people Cutoff ill patients Marker concentration Ideal situation: does not exist
15 The sensible use of biomarkers in clinical practice Cut-off Healthy people ill patients Marker concentration False negative and false positive findings are a function of the chosen cut-off: the higher the specificity, the lower the sensitivity and vice versa.
16 The sensible use of biomarkers in clinical practice Cut-off Healthy people ill patients High specificity less healthy are false positive, but more patients having a disease are false negative Marker concentration
17 The sensible use of biomarkers in clinical practice Healthy people Cutoff ill patients High sensitivity all people having a disease are being detected, but more false positives Marker concentration
18 Sensitivity Specificity NPV -PPV Biomarker Disease Present Absent Positive A B A + B Negative C D C + D A + C B + D A + B + C +D Disease prevalence: A + C / A + B + C + D Specificity: D / B + D Sensitivity: A / A + C Negative likelihood ratio (LR-): (1 sensitivity)/specificity Negative predictive value: D / C + D Positive likelihood ratio (LR+): sensitivity/(1-specificity) Positive predictive value: A / A +B
19 The Area Under an ROC Curve The accuracy of the test depends on how well the test separates the group being tested into those with and without the disease in question = excellent (A) = good (B) = fair (C) = poor (D) = fail (F)
20 Agenda Introduction Sensitivity Specificity - ROC Biomarkers with added medical value: IL-6 Biomarkers with added medical value: S100 Biomarkers with added medical value: TnT hs Biomarkers with added medical value: NT-proBNP Biomarkers with added medical value: Cystatin C Conclusion
21
22 IL-6: An early, sensitive marker of inflammation often the first indication of critical disease
23 IL-6 Biochemistry - Summary 184 amino acids glyco-protein and has a molecular weight of about 26 kd. Released by many cells. Multiple biological actions on different types of target cells via receptors and gp130. Substantial impact on the immune system, hematopoesis, and inflammation. Longest half-life of the pro-inflammatory mediators in the systemic circulation. Activation time: very short Half-life time: about 1 hour IL-6 triggers the production and release of CRP in the liver. IL-6 triggers to a certain extent procalcitonin. Early and sensitive alarm marker for (systemic) inflammation and sepsis and neonatal sepsis.
24 IL-6 Procalcitonin -CRP Polytrauma patient gallbladder surgery Day 4-5 : sepsis Patient 205, male, 65 years data Feldkirch IL-6 CRP PCT IL-6 [pg/ml] CRP [mg/l] PCT [ng/m L] IL CRP PCT day
25 IL-6 Procalcitonin -CRP Day 5: severe sepsis Day 6-8: signs of sepsis Patient 210, male, 70 years data Feldkirch IL-6 CRP PCT IL-6 [pg/ml] CRP [mg/l] PCT [ng/ml] IL CRP PCT day
26 IL-6 Procalcitonin -CRP Day 1-3 sepsis Patient 204, male, 77 years data Feldkirch IL-6 CRP PCT IL-6 [pg/ml] CRP [mg/l] PCT [ng/ml] IL CRP PCT day
27 IL-6: Values of Crit. Care Patients IL-6 (pg/ml) 7 pg/ml * Median Mean Min Max N SIRS * Reference Healthy Sepsis Severe Sepsis Septic Shock n= 281 IL-6 values increase steadily with severity of the disease.
28 Procalcitonin: Values of Crit. Care Patients PCT (ng/ml) 0.05 ng/ml * Median Mean Min Max N SIRS * Reference Healthy Sepsis Severe Sepsis Septic Shock n= 281 Procalcitonin distinct increase are seen only from severe sepsis on.
29 Sepsis Markers IL-6 is an early and sensitive alarm marker for (systemic) inflammation and sepsis. Initiated by IL-1 and TNFα appearenance assumed within 1hour half-life ~ 1 hour (hs)crp Initiated by IL-6 appearance ~ h after IL-6 half-life ~ approx. 20 h PCT due to its later increase and longer half-life is a confirmation of (bacterial) sepsis. Initiated by endotoxins, IL-6 and (??) not known appearance ~ 24 hours after IL-6 half-life ~ approx. 24 h The three markers do not replace each other. In contrary -used combined they add significant information regarding the status and the severity of the disease.
30 Agenda Introduction Sensitivity Specificity - ROC Biomarkers with added medical value: IL-6 Biomarkers with added medical value: S100 Biomarkers with added medical value: TnT hs Biomarkers with added medical value: NT-proBNP Biomarkers with added medical value: Cystatin C Conclusion
31 S100 The Parameter: The unfractionated protein mixture isolated from bovine brain was solublein 100% saturated ammonium sulfate solution.
32 S100: The Parameter S100 mrna Distribution S100 belongs to a family of calcium-binding proteins. Up to now 21 members are identified It s molecular weight is approximately 10.5 kd. S100 A1(α) and S100 B (β) occur mostly as homo- or hetero-dimers. S100A0 S100A1 colon, S100A2 muscle, S100A4 spleen, stomach, S100A7 thymus, S100A8 S100A9 S100A10 S100B colon, skin, S100C S100P CaLB3 S100F kidney, heart brain, aorta, bladder, fat, heart, kidney, intestine, pancreas,skeletal muscle, spleen, testes, uterus, melanoma cells kidney, lung, skeletal mammary epithelial lung, skeletal muscle, nerve, thymus, fibroblasts, bone marrow, lymphocytes heart, lung, stomach, fibroblast, neuroblasts (monocytes monocytes kidney, nerve brain, aorta, bladder, fat, intestine, pancreas, skeletal muscle, testes, nerve, melanoma cells heart, kidney, lung, adrenal gland, fibroblasts placenta liver, intestine skin
33 S100B: The Parameter S100 A1 und B is predominantly found in astrocytes, glia cells, and Schwann cells It can be detected in the systemic circulation when the BBB opens temporarily. S100 S100 Urban & Fischer 2003 Roche Lexikon Medizin
34 S100: Three distinct clinical indications Monitoring melanoma patients stage III and IV Exclusion of minor traumatic brain injury (MTBI) Monitoring primary/secondary brain injury in severe traumatic brain injury intracranial hemorrhage e.g. after severe stroke or subarachnoidal hemorrhage patients after cardiac or bypass surgery sepsis patients
35 S100 Values in Mild Traumatic Brain Injury Patients and Healthy patients Results
36 S100 Values in Mild Traumatic Brain Injury Patients and Healthy patients Results
37 Prospective Study Results: Contingency Table Patients GCS 13 15: N = 1309 [µg/l] S100-Value * S µg/l S100- < 0.10 µg/l CCT + CCT * CCT- *= p<0.001 U-Test CCT+ Sensitivity: 98.9 % ( % CI 95) Specificity: 31.6 % ( % CI 95) NPV: 99.7 % ( % CI 95) PPV: 10 % ( % CI 95) Biberthaler P. et al. SHOCK, Vol. 25, No. 5, pp , 2006 *= µg/l
38 Prospective Study Results S100 Values by GCS Score CCT+ CCTcut-off 0.1µg/L N =1309 S-100B in [µg/l] * * * # *=p<0.001 U-test CCT+ vs. CCT- #=p<0.05 ANOVA/Dunn s GCS 15 vs. 13/14 GCS Score Biberthaler P. et al. SHOCK, Vol. 25, No. 5, pp , 2006
39 39
40 Methodology Studies containing adult patients with nonpenetrating head injury GCS score 13 S100B serum & cranial CT scan within 24 hours of injury 272 abstracts & 49 full manuscripts were chosen 12 studies were found eligible and selected containing 2466 patientsfrom Sweden, Norway, Germany, France, Slovenia, Brazil, and the United States. Time from injury to S100B sampling ranged from less than 3 hours to less than 24 hours. All were emergency departments Cutoff S100B = 0,10 µg/l 40
41 Table showing the 12 eligible studies with true positives (S100+, CT+), false positives (S100+, CT ), false negatives (S100, CT+), true negatives (S100, CT ). NPV = 99,2% The studies were graded and assigned a quality rating with respect to the key question according to the Centre of Evidence Based Medicine (CEBM) criteria. The final recommendation (A to D) is based on CEBM criteria; grade A referring to consistent class 1 studies, grade B for consistent level 2 or 3 studies (or extrapolations from level 1 studies), grade C for level 4 studies (or extrapolations from level 2 or 3 studies), and grade D for level 5 studies. 41
42 The 12 eligible studies show similar results with high individual sensitivities. The pooled sensitivity for all studies was 97%(95% CI 91% 99%) and the pooled specificity 40%(95% CI 30% 51%). 42
43 Conclusions: Very high individual NPVs (90% 100%) for the ability of a negative (under cutoff level = 0,10µg/L) S100B level to predict a normal CT scan. Sensitivity NPV D Dimer Pulmonary embolism 95% 99% D Dimer Deep vein thrombosis 88/90/92% 99/96/84% Myoglobine Acute Myocard infarction 61% 87% Troponin T Acute Myocard infarction 73% 91% S100B Minor Head Injury 97% 99% S100B (half-life ): should therefore be taken within 3 hours of injury. S100B does is not affected by alcohol intoxication in head-injured patients. S100B has to be used as a rule out marker for minor head injuriesand by this helps to reduce the number of routine CT examinations. S100B gives additional information to CCT scan in axonal injury or early after accident 43
44 Agenda Introduction Sensitivity Specificity - ROC Biomarkers with added medical value: IL-6 Biomarkers with added medical value: S100 Biomarkers with added medical value: TnT hs Biomarkers with added medical value: NT-proBNP Biomarkers with added medical value: Cystatin C Conclusion
45 History of markers for acute myocardial infarction AST enzyme in AMI CK enzyme in AMI CK-MB enzyme inhition activity CK / LD isoenzymes electrophor. Myoglobin RIA CK-MB mass immunoassay ctnt ctni hs-tns precommercial TnT hs launched st WHO criteria for AMI th WHO criteria for AMI 1979 WHO MONICA criteria for AMI Redifinition of AMI 2007 Universal definition of MI ESC guidelines - NSTEMI 2010
46 Temporal pattern of release after the onset of AMI Kinetic Magnitude of elevation varies with infarct size French, J. and White, H. (2004). Heart 90(1): ULRR = upper limit of reference range 30 November 2012 page Roche
47 Biomarkers in Acute Coronary Syndrome Detection, sensitivity and specificity for AMI Markers First Detection Duration of Detection Sensitivity Specificity Myoglobin h 8-12 h CK-MB 2 3 h 1-2 d Troponin I 3 4 h 7-10 d Troponin T 3 4 h 7-14 d CK Total 4 6 h 2-3 d Individuals can deviate from this pattern, it has been reported that 15% of patients have discordant TnT and CK-MB results, perhaps due to timing but also inter and intraindividual variations. Successful reperfusion in AMI patients accelerates the cardiac marker release. *TIMI: Thrombolysis in Myocardial Infarction French JK, White HD. Clinical implications of the new definition of myocardial infarction. Heart (2004) 90: November 2012 page Roche
48 Cardiac Troponin T and Troponin I Major circulating forms Ternary complex Binary complex Free form Both ctnt and ctni are found circulating in different forms: as ternary complex, binary complex (mainly TnI-TnC) and free forms 1 Free TnT is the major TnT circulating form 2 Cardiac TnI is highly susceptible to proteolysis and enzymatic modification. Multiple circulating TnI forms are described 3 : Proteolysed forms Complexed to heparin or not Phosphorylate forms Oxidized and reduced forms Degradation can occur both in vitro and in vivo challenging consistency of TnI measurements 1 Korff S et al. Heart, 2006; 92: ; 2 Wu A et al. Clin Chem 1998; 44: ; 3 Katrukha A et al. Clin Chem 1997; 43:
49 Universal definition of myocardial Expert consensus document by the joined ESC/ACCF/AHA/WHF task force infarction, 2007 The term myocardial infarction should be used when there is evidence of is evidence of myocardial ischemia. Under these conditions any one of the following criteria meets the diagnosis for myocardial infarction: Detection of rise and/or fallof cardiac biomarkers (preferably troponin) with at least one value above the 99 th percentile in combination with at least one of the following: Symptoms of ischemia ECG changes indicative for ischemia : ST-T changes or new LBBB or new Q-waves Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality Optimal precision (coefficient of variation [CV]) at the 99 th percentile upper reference limit [URL]) should be defined as 10%. The use of assays that do not have independent validation of optimal precision (CV 10%) is not recommended. Thygesen K et al. JACC 2007; 50 (22):
50 Universal definition of MI By the joined ESC/ACCF/AHA/WHF task force MI definition Increase of Troponin Thygesen K et al. Eur Heart J 2012
51 TnT-hs distribution of values: Reference population 90 The overall imprecision of the ctnt-hs assay fulfils current guideline recommendations th percentile URL value from 533 healthy volunteers : 14 pg/ml and 10% CV at 13 ng/l 60 Frequency th percentile 14,2 ng/l (reference limit) Elecsys TnT-hs [ng/l] Saenger AK et al. Clin Chim Acta 2011; 412(9-10): The limit of blank and limit of detection were 3 and 5 ng/l, respectively
52 Troponin assay precision requirements The first criteria of Fred Apple s scorecard 1 Analytical criterion recommended by the international guidelines: a total imprecision equal to or less than 10% at the 99 th percentile value 2,3 Total imprecision at the 99 th percentile, CV % 10 Acceptance designation Guideline acceptable >10 to 20 Clinically usable > 20 Not acceptable 1. Apple FS. A new season for cardiac troponin assays: It s time to keep a scorecard. Clin Chem 2009;55: Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction: Universal definition of myocardial infarction. JJAm Coll Cardiol 2007; 50, Morrow DA, Cannon CP, Jesse RL et al. National Academy of Clinical Chemistry laboratory medicine practice guidelines; clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Clin Chem 53,
53 Progress in cardiology Influence of sensitivity and precision on early detection Normal ctn turnover range of Tn rise 2-6 h post event 6-8 h post event Adapted from: Hochholzer W et al. Am Heart J 2010; 160(4):
54 Acute chest pain AMI 2 problems: Rule in & Rule out O h 1 h 2 h 3 h 4 h 5 h 6 h 7 h ECG 1 CTn 2 CTn Delay in adequate therapy Morbidity Cost Patient: Anxiety,
55 Clinical validation Non STEMI patients ctnt-hs (% positive) depending on time after onset of symptom in patients developing NSTEMI 100 % ctnt-hs all ctnt-hs early (< 4h) ctnt- hs late (>4h) The ctnt-hs assay identified 20% more patients with a final diagnosis of NSTEMI than ctnt Gen 4 Time to diagnosis of NSTEMI was made a mean of 175 min (2h55 min) earlier with ctnths than with ctnt Gen reference ctnt Gen 4 Admission1h 2h 3h 4h 5h 6h 24h A 2 cd measurement within 3-5 h after admission considerably improved ctnths performance Adapted from: Giannitsis et al. Clin Chem 2010; 56 (2), November 2012 page Roche hours after admission
56 Clinical added value Earlier diagnostic of AMI, the 1 st supporting facts The diagnostic performanceof the novel Tn assays was very high at presentationand significantly higher than the standard TnT gen 4 assay TnT-hs improved by 21%the earlier diagnostic of AMI TnT-hs demonstrated the highest sensitivity (95%) The high NPV (99%)confirmed that the novel sensitive Tn assays may help for the reliable rule out of AMI 30 November 2012 page Roche
57 Cardiac TnT-hs to diagnose MI Using the 99 th percentile and criteria for fall and rise of ctn Patient with symptoms of MI* Baseline ctnt-hs <14 ng/l 14 to < 53 ng/l 53 ng/l Retest ctnt-hs 6 hours later to rule out MI Retest ctnt-hs 3 hours later Retest ctnt -hs 3 hours later Change <50% Change 50% Change <20% Change 20% Adverse prognosis Retest ctnt-hs at 6, 12 hours Myocardial infarction * To make the diagnosis of MI, there must also be evidence of ischemia manifesting as symptoms or evident on electrocardiogram, imaging evidence of new loss of viable myocardium or new regional wall motion abnormality Adapted from: White H Am Heart J 2010;159(6): November 2012 page Roche
58 20 Keller T et al. New England J Med 2009; 361: Riechlin T et al. New England J Med 2009; 361: Giannitsis et al. Clin Chem 2010; 56: Weber M et al. Am Heart J 2011; 162: Source: Eur Heart J 2011; 32(23): November 2012 page Roche
59 Absolute and relative changes in cardiac troponin Reichlin T et al. Circ 2011; 124(2): ROC curves of 1-hour (A) and 2-hour (B) ctn changes ctnt-hs absolute change Sensitivity Sensitivity ctni Ultra absolute change ctnt-hs relative change ctni Ultra relative change specificity A specificity B ROC-optimised delta change for ctnt-hs: 7 ng/l The accuracy of absolute ctn changes for the diagnosis of AMI was high for both assays after both 1 and 2 hours, and was significantly higher than that of relative changes at both time points 30 November 2012 page Roche
60 Absolute and relative changes in cardiac troponin Mueller M et al. ClinChem2012; 58(1): Prediction of non-stemi in the entire study population A 1.0 B 1.0 Prediction of non-stemi in ACS patients Sensitivity Absolute change (AUC=0.898)* Relative change (AUC=0.752) Baseline ctnt-hs (AUC=0.731) Peak ctnt-hs (AUC=0.830) Sensitivity Absolute change (AUC=0.941)* Relative change (AUC=0.741) Baseline ctnt-hs (AUC=0.836) Peak ctnt-hs (AUC=0.894) specificity 1 specificity ROC-optimised absolute delta change: 9.2 ng/l ROC-optimised absolute delta change : 6.9 ng/l Absolute ctnt-hs changes had the highest AUC for the prediction of non-stemi 30 November 2012 page Roche
61 Elevated ctnt-hs in patients with ACS Celik S. et al. Clin Res Cardiol 2011;100(12): Results: Kaplan-Meier survival A: survival B : event free survival (composite endpoint, death/mi) among patients with ctnt Gen4 below the 99 th percentile (<0.01 µg/l) according to ctnt-hs level (A) 100 Survival probability (%) ctnt-hs <14 ng/l (n=285; events=1) ctnt-hs 14 ng/l (n=169; events=9) Logrank p= (B) Survival probability (%) ctnt-hs 14 ng/l (n=169; events=12) Logrank 6.42 p=0.011 ctnt-hs <14 ng/l (n=285; events=6) Time (days) Time (days) Rates of both all-cause of death and the composite of death/non-fatal MI were significantly higher when ctnt-hsvalues exceeded the 99 th percentile, particularly in patients with ctntgen4 <99 th percentile
62 Cardiac TnT-hs predicts risk in general population In coronary heart disease, death & heart failure -ARIC study ctnt-hs levels are associated with incident CHD, mortality and HF in individuals from a general population without known cardiovascular disease (n=9698 individuals) Risk of Coronary Heart Disease over time 30 by ctnt-hs level 30 Risk of death over time by ctnt-hs level 30 Risk of Heart Failure over time by ctnt-hs level ctnt-hs quintile Quintile Quintile 4 Risk (%) Quintile 3 Quintile 2 Quintile Follow-up years Follow-up years Follow-up years The ctnt-hs assay identifies patients at risk of future cardiovascular events Source: Saunders, JT. et al. (2011) Circ 23(13): November 2012 page Roche
63 Conclusions The 99th percentile hs-ctn URL value should be used as the decision limit for the diagnosis of AMI. The ctnt-hs assay meets the 10% CV criterion at the 99 th percentile URL. The diagnosis of acute myocardial necrosis requires a significant change with serial testing. At low baseline ctn (around the 99th percentile): marked change is required (> 50% ) In case of markedly elevated baseline ctn: change of > 20% is required The improved sensitivity leads to an earlier diagnosis of AMI: Sensitive troponin assays detect patients with AMI already at 2 hours after onset of symptoms The new ctnt-hs assay helps for risk stratification of ACS The ctnt-hs assay identifies patients at risk of future cardiovascular events As recommended by the guidelines, ctn results have to interpreted with the clinical presentation of the patient; and acute changes in serial samples are required to differentiate acute from chronic myocardial damage
64 Agenda Introduction Sensitivity Specificity - ROC Biomarkers with added medical value: IL-6 Biomarkers with added medical value: S100 Biomarkers with added medical value: TnT hs Biomarkers with added medical value: NT-proBNP Biomarkers with added medical value: Cystatin C Conclusion
65 Heart failure in Belgium: HF has a significant impact on the health care costs in Belgium. The mean in-hospital stayfor HF = 13 days 1 Total in-hospital stay for HF of 254,826 days. HF accounts for 5% of all emergencymedical admissionsto a hospital 1 30%of the patients are re-admissed within 6 months and50% within a year, depending on the level of severity % hospitalisation costs are due to rehospitalisations. The mortality rate is ~50% over 5 year. 30/11/ Data RIZIV Data Unamec 2011
66 Diagnosis of heart failure Overview HF is a diagnostic challenge 50 % of the patients referred to cardiologists have originally been misdiagnosed Patients usually are older and have more than one disease Diagnosis of underlying disease is crucial for treatment Diagnostic procedure Is it heart failure? What is the underlying disease? Diagnostic measures Symptoms Physical findings, clinical signs Blood marker (NT-proBNP) Chest X-ray Echocardiography Braunwald E, 2001.
67 The diagnosis of heart failure was confirmed in 40 (29%) patients. An abnormal ECG did not add any further predictive value to that of NTproBNP. Zaphiriou A. et al. The diagnostic accuracy of plasma BNP and NT-proBNP in patients referred from primary care with suspected heart failure: Results of the UK natriuretic peptide study. Eur J Heart Fail 2005;7: Nielsen et al. N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea. Eur J Heart Fail, 2004,6:63-70.
68 NT-proBNP Biology and biochemistry I 1988 Brain natriuretic peptide (BNP) is discovered Natriuretic peptides are released when the heart muscle is stretched: Atrial Natriuretic Peptide (ANP): from myocardial cells of the atrium. Brain Natriuretic Peptide (BNP): from myocardial cells of the ventricles, BNP is also formed in the brain. Other natriuretic peptides C-type natriuretic peptide (CNP): mainly present in vascular tissue Urodilatin: produced by the kidney, function is unclear Spanuth, 2004; Haas, hypertrophy Normal heart ANP NT-proANP BNP NT-proBNP Heart failure ANP NT-proANP BNP NT-proBNP
69 NT-proBNP Biology and biochemistry II Action of BNP: reduces the volume load in the heart by increasing urination (= diuretic) increasing elimination of sodium (= natriuretic) reducing blood pressure i.e., BNP counteracts activated reninangiotensin-aldosterone system Structure 32 amino acids 17-amino acid ring structure essential for activity NT-proBNP is formed by cleavage of probnp pre-probnp probnp N-terminal probnp BNP Half life 120 min. 20 min. Biological effects No Yes Heart muscle Spanuth, 2004; Haas, 2005.
70 NT-proBNP Differences vs. BNP NT-proBNP vs. BNP NT-proBNP Hormonally inactive BNP Hormonally active 76 amino acids 32 amino acids Half-time: min Higher plasma levels, cumulative concentrations reflect whole cardiac situation Up to 3 days stable at room temperature No interference by therapeutics 20 min Lowerplasma levels, depend on the patient's situation at the moment Less stable Interference by therapy with BNP or degradation inhibitors of natriuretic peptides Arguments for NT-proBNP Larger peptide, longer half-life More diagnostic power, less susceptible to clearance mechanisms Higher plasma concentration Easier to measure, more diagnostic resolution Lower intra-individual variation better early detection Analytical differences More stable, more precise, better detection Yeo et al., 2003; Mueller et al., 2004;
71 The natriuretic peptides Biochemistry of NT-proBNP cardiomyocyte -26 amino acid 108 pre-probnp probnp signal NT-proBNP BNP BNP (physiologically active)
72 The Natriuretic Peptides The peptide family 1988 Brain natriuretic peptide (BNP) is discovered Four peptides related with each other regarding biochemisty and physioglogical function: - atrial natriuretic peptide (ANP) - brain (or B-type) natriuretic peptide (BNP) - C-type natriuretic peptide (CNP) - urodilatin, a slightly extended form of ANP Biochemistry - common 17-amino acid ring structure - ring structure highly conserved - 11/17 amino acids are homologous -ring structure essential for physiological activity Physioglogical function diverse effects on tissues involved in sodium regulation and blood pressure homeostasis
73 NT-proBNP correlates with NYHA class Acute phase Chronic phase Januzzi J.L. et al. Use of Amino-Terminal Pro-B-Type Natriuretic Peptide to Guide Outpatient Therapy with Chronic Left Ventricular Systolic Dysfunction. J Am Coll Cardiol 2011;58: Januzzi J. L. et al.: Utility of Amino-Terminal Pro Brain Natriuretic Peptide Testing for Prediction of 1-Year Mortality in Patients With Dyspnea Treated in the Emergency Department. Arch Intern Med. 2006;166:
74 Have natriuretic peptides an added clinical value? Januzzi J.L. et al. The N-Terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. Am J Cardiol 2005;95:
75 Cut-off values for NT-proBNP: chronic heart failure <400 pg/ml 75
76 Cut-off values for NT-proBNP: acute heart failure PPV = 92% PPV = 76% PPV = 82% NPV = 98% 76
77 Negative predictive value
78 RULE-OUT of heart failure = faster
79 Relationmortality/BNP-concentration acute HF
80 Change of NT-proBNP during hospital stay predicts death or readmission P. Bettencourt et al. Circulation 2004; 110: Cumulative survival and no-readmission according to the change of NT-proBNP levels during hospital stay n Events Decrease 82 27% > 30% Change < 30% 49 49% Increase 25 84% > 30%
81 Creatinine values Relationship NT-proBNP values and renal function Hemodynamics Neurogenic reflexes Hormones (RAAS, NP s) N = NT-proBNP values
82 Agenda Introduction Sensitivity Specificity - ROC Biomarkers with added medical value: IL-6 Biomarkers with added medical value: S100 Biomarkers with added medical value: TnT hs Biomarkers with added medical value: NT-proBNP Biomarkers with added medical value: Cystatin C Conclusion
83 Acute Kidney Injury Biomarkers
84 Cystatin C: properties and advantages as a GFR marker Non-glycosylated, single chain protein of 13.3 kda molecular weight. Synthesized by all nucleated cells at a constant rate. Freely filtered by the glomerulus. Reabsorbed by tubular epithelial cells and subsequently degraded. Serum concentration not affected by muscle mass, gender, inflammation, and age. Elimination only via filtration (no secretion, no reentering in circulation). These characteristics make Cystatin C a valuable marker for the estimation of GFR.
85 Kidney Biomarkers The quest for the practical Kidney function marker CREATININE: Well established but, important blind window CYSTATIN-C : Novel marker with improved sensitivity PROTEIN: late marker for protein leakage N-GAL: Marker for acute kidney failure CREATININE blind window Cystatin-C 30 November, 2012 page Roche
86 How to determine kidney function
87 The problem of the Creatinine-blind area in serum- Creatinine based GFR assessments GFR :Kidney Function Cystatin C Creatinine GFR GFR Schematic correlation of GFR with serum Creatinine and Cystatin C concentrations (redrawn from Künzi T (2005)) Creatinine-blind Area The same change in GFR causes a greater change in Cystatin C- than in Creatinine concentration. Thus, early changes in GFR can be detected easily employing Cystatin C-Assays, while may go undetected with Creatininebased GFR assessments. Crea Concentration Cys C Bio-marker concentration
88 Cystatine C vs. Serum Creatinine 30 November, 2012 page Roche
89
90 Agenda Introduction Sensitivity Specificity - ROC Biomarkers with added medical value: IL-6 Biomarkers with added medical value: S100 Biomarkers with added medical value: TnT hs Biomarkers with added medical value: NT-proBNP Biomarkers with added medical value: Cystatin C Conclusion
91 Summary IL-6 is an unspecific inflammation marker...but is alsosensitive, an early marker, on-time (due to short half-life) and mirrors the actual situation regarding inflammation. S100 below 0,10 µg/l excludes brain injury with high likelyhood and helps to reduce the number of routine CT scans. ctnt-hs has an improved sensitivity that leads to an earlier diagnosis of AMI and helps for risk stratification of ACS (NT-pro)BNP is a very powerful marker for rule-in/rule-out & prognosis of heart failure and NT-proBNP guided therapy reduces mortality and hospitalization in heart failure patients Cystatin C is a more sensitive marker of GFR than creatinine and is not affected by age, diet or body mass.
92 Biomarkers are only a mark Questions? 92
93 We Innovate Healthcare 93
Mario Plebani University-Hospital of Padova, Italy
Mario Plebani University-Hospital of Padova, Italy CK-MB mass assay CHF guidelines use BNP for rule out AST in AMI CK in AMI INH for CK-MB electrophoresis for CK and LD isoenzymes RIA for myoglobin WHO
More informationEDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE
EDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE
More informationCardiac Troponin Testing and Chest Pain Patients: Exploring the Shades of Gray
Cardiac Troponin Testing and Chest Pain Patients: Exploring the Shades of Gray Nichole Korpi-Steiner, PhD, DABCC, FACB University of North Carolina Chapel Hill, NC Learning Objectives Describe the acute
More informationHigh Sensitivity Troponin Improves Management. But Not Yet
High Sensitivity Troponin Improves Management But Not Yet Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory Medicine
More information10 Ways to Make the Use of High Sensitivity Cardiac Troponin Values Easier and Better
10 Ways to Make the Use of High Sensitivity Cardiac Troponin Values Easier and Better Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department
More informationHigh Sensitivity Troponins. IT S TIME TO SAVE LIVES. Updates from the ESC 2015 Guidelines November 17th 2016 OPL CONGRESS Dr.
High Sensitivity Troponins. IT S TIME TO SAVE LIVES. Updates from the ESC 2015 Guidelines November 17th 2016 OPL CONGRESS Dr. Marcel El Achkar Chairperson of Laboratory department Nini Hospital Lecturer
More informationBiomarkers in Acute Cardiac Disease Samir Arnaout, M.D.FESC Associate Professor of Medicine Internal Medicine i & Cardiology American University of Beirut Time course of the appearance of various markers
More informationTroponin when is an assay high sensitive?
Troponin when is an assay high sensitive? Professor P. O. Collinson MA MB BChir FRCPath FRCP edin MD FACB EurClin Chem Consultant Chemical Pathologist and Professor of Cardiovascular Biomarkers, Departments
More informationhs-c Tn I high sensitivity troponin I <17 min
hs-c Tn I high sensitivity troponin I IFCC & ESC compliant 0/ h NSTEMI rule-out / rule-in algorithm POCT whole blood/plasma Results in < 7 minutes
More informationHow will new high sensitive troponins affect the criteria?
How will new high sensitive troponins affect the criteria? Hugo A Katus MD Abteilung Innere Medizin III Kardiologie, Angiologie, Pulmologie Universitätsklinikum Heidelberg Even more sensitive: The new
More informationTroponin Assessment. Does it Carry Clinical Message? Stefan Blankenberg. University Heart Center Hamburg
Biomarkers for Optimal Management of Heart Failure Troponin Assessment Does it Carry Clinical Message? Stefan Blankenberg University Heart Center Hamburg Congress of the European Society of Cardiology
More informationDefining rise and fall of cardiac troponin values
Defining rise and fall of cardiac troponin values Doable but Not Simple Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory
More information7/31/2018. Overview of Next Generation Cardiac Troponin T High Sensitivity. Disclosures. Course Objectives: high sensitive Troponin T assay
Overview of Next Generation Cardiac Troponin T High Sensitivity Arleen Francis Medical & Scientific Liaison Roche Diagnostics 1 Disclosures Arleen Francis is an employee of Roche Diagnostics and a member
More informationUse of Biomarkers for Detection of Acute Myocardial Infarction
Use of Biomarkers for Detection of Acute Myocardial Infarction Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory Medicine
More informationCurrent Utilities of Cardiac Biomarker Testing at POC. June 24, 2010 Joe Pezzuto, MT (ASCP) Carolyn Kite, RN
Current Utilities of Cardiac Biomarker Testing at POC June 24, 2010 Joe Pezzuto, MT (ASCP) Carolyn Kite, RN 1. Discuss challenges associated with diagnosing Acute Coronary Syndromes (ACS) and Heart Failure
More informationRapid detection of myocardial infarction with a sensitive troponin test Scharnhorst, V.; Krasznai, K.; van 't Veer, M.; Michels, R.
Rapid detection of myocardial infarction with a sensitive troponin test Scharnhorst, V.; Krasznai, K.; van 't Veer, M.; Michels, R. Published in: American Journal of Clinical Pathology DOI: 10.1309/AJCPA4G8AQOYEKLD
More informationBioRemarkable Symposium
BACC BioRemarkable Symposium Acute Myocardial infarction Stefan Blankenberg University Heart Center Hamburg London, September 7th, 2017 Universitätsklinikum Hamburg-Eppendorf Third Universal-Definition
More informationHigh-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients with Stable Coronary Heart Disease: KAROLA Study 8 Year FU
ESC Congress 2011 Paris, France, August 27-31 KAROLA Session: Prevention: Are biomarkers worth their money? Abstract # 84698 High-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients
More information9/18/2017. Disclosures. Cardiac Troponin: ER Utilization and the Next Generation
Disclosures Cardiac Troponin: ER Utilization and the Next Generation Joshua Soldo is an employee of Roche Diagnostics within the division of Medical Scientific Affairs. Data presented is intended for purely
More informationIFCC Task Force on Clinical Applications of Cardiac Biomarkers (TF-CB) Report to the General Conference 2016 Madrid
IFCC Task Force on Clinical Applications of Cardiac Biomarkers (TF-CB) Report to the General Conference 2016 Madrid 1 CREATED By the EB in 2011, following to the Committee on Standardization of Cardiac
More informationSupplementary Online Content
Supplementary Online Content Rubini Giménez M, Twerenbold R, Boeddinghaus J, et al. Clinical effect of sex-specific cutoff values of high-sensitivity cardiac troponin T in suspected myocardial infarction.
More informationΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ. ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας
ΕΘΝΙΚΟ ΚΑΙ ΚΑΠΟΔΙΣΤΡΙΑΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΑΘΗΝΩΝ ΙΑΤΡΙΚΗ ΣΧΟΛΗ Ά ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ Διευθυντής: Καθηγητής Δημήτριος Τούσουλης ΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας
More informationQuantitative measurement of 6 analytes in parallel hs Trop I, NTproBNP, D-Dimer, hscrp, Myoglobin, HCG, CK-MB mass
Quantitative measurement of 6 analytes in parallel hs Trop I, NTproBNP, D-Dimer, hscrp, Myoglobin, HCG, CK-MB mass High Sensitivity NEW MARKER Tr o p o n in I EMERGENCY & CRITICAL CARE» 6 samples in parallel»
More informationÄr dagens troponinmetoder tillräckligt känsliga?
Är dagens troponinmetoder tillräckligt känsliga? Per Venge, MD PhD Professor Department of Medical Sciences Uppsala University and Department of Clinical Chemistry and Pharmacology University Hospital
More informationHigh-Sensitivity Cardiac Troponin in Suspected ACS
15 th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes STATE-OF-THE-ART High-Sensitivity Cardiac Troponin in Suspected ACS David A. Morrow, MD, MPH Director, Levine Cardiac Intensive Care
More informationQuantitative measurement of 6 analytes in parallel
Quantitative measurement of 6 analytes in parallel Trop I sensitive, NTproBNP, D-Dimer, hscrp, Myoglobin, HCG, CK-MB mass NEXT GENERATION PATHFAST TM emergency & CRITICAL CARE» 6 samples in parallel» in
More informationTROPONINS HAVE THEY CHANGED YOUR
TROPONINS HAVE THEY CHANGED YOUR PRACTICE THIS WEEK? Harvey White John Neutze Scholar Green Lane Cardiovascular Service and Cardiovascular Research Unit Auckland City Hospital, Auckland, New Zealand Disclosure
More informationNew diagnostic markers for acute coronary syndromes
New diagnostic markers for acute coronary syndromes - Nye diagnostiske markørerer for akutt iskemisk hjertesykdom Bertil Lindahl, Professor Cardiology, Uppsala University and Uppsala Clinical Research
More informationBiomarkers of myocardial infarction. Dr. Mamoun Ahram Cardiovascular system, 2013
Biomarkers of myocardial infarction Dr. Mamoun Ahram Cardiovascular system, 2013 References This lecture Hand-outs Acute Myocardial Infarction A rapid development of myocardial necrosis caused by prolonged
More informationDIAGNOSTICS ASSESSMENT PROGRAMME
DIAGNOSTICS ASSESSMENT PROGRAMME Evidence overview Early rule out or diagnosis of acute myocardial infarction: High-sensitivity troponin tests (Elecsys troponin T high-sensitive, ARCHITECT STAT highsensitivity
More informationBiomarkers in cardiovascular disease. Felix J. Rogers, DO, FACOI April 29, 2018
Biomarkers in cardiovascular disease Felix J. Rogers, DO, FACOI April 29, 2018 Biomarkers NIH: A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological
More informationWhat can we learn from EQAs and audits for cardiac marker testing?
What can we learn from EQAs and audits for cardiac marker testing? Dr P. O. Collinson MA MB BChir FRCPath MD FACB Consultant Chemical Pathologist and Director of Clinical Blood Sciences, Head of Vascular
More informationMeasuring Natriuretic Peptides in Acute Coronary Syndromes
Measuring Natriuretic Peptides in Acute Coronary Syndromes Peter A. McCullough, MD, MPH, FACC, FACP, FAHA, FCCP Consultant Cardiologist Chief Academic and Scientific Officer St. John Providence Health
More informationTo estimate the serum level of N-terminal pro-brain natriuretic peptide levels in acute coronary syndrome
Original Research Article To estimate the serum level of N-terminal pro-brain natriuretic peptide levels in acute coronary syndrome Mohamed Yasar Arafath 1, K. Babu Raj 2* 1 First Year Post Graduate, 2
More informationUndetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction
Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction Nadia Bandstein, MD; Rickard Ljung, MD, PhD; Magnus Johansson, MD, PhD; Martin Holzmann,
More informationImpact of Troponin Performance on Patient Care
Impact of Troponin Performance on Patient Care Linda C, Rogers PhD, DABCC, FACB Agenda Introduction Diagnosis of MI Guidelines Troponin Assay differences Classification of troponin assays Guideline acceptable
More informationNatriuretic Peptides The Cardiologists View. Christopher defilippi, MD University of Maryland Baltimore, MD, USA
Natriuretic Peptides The Cardiologists View Christopher defilippi, MD University of Maryland Baltimore, MD, USA Disclosures Research support: Alere, BG Medicine, Critical Diagnostics, Roche Diagnostics,
More informationAcute coronary syndrome. Dr LM Murray Chemical Pathology Block SA
Acute coronary syndrome Dr LM Murray Chemical Pathology Block SA13-2014 Acute myocardial infarction (MI) MI is still the leading cause of death in many countries It is characterized by severe chest pain,
More informationPost-Procedural Myocardial Injury or Infarction
Post-Procedural Myocardial Injury or Infarction Hugo A Katus MD & Evangelos Giannitsis MD Abteilung Innere Medizin III Kardiologie, Angiologie, Pulmologie Universitätsklinikum Heidelberg Conflict of Interest:
More informationSupplementary material 1. Definitions of study endpoints (extracted from the Endpoint Validation Committee Charter) 1.
Rationale, design, and baseline characteristics of the SIGNIFY trial: a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical
More informationHeart Failure and Cardio-Renal Syndrome 1: Pathophysiology. Biomarkers of Renal Injury and Dysfunction
CRRT 2011 San Diego, CA 22-25 February 2011 Heart Failure and Cardio-Renal Syndrome 1: Pathophysiology Biomarkers of Renal Injury and Dysfunction Dinna Cruz, M.D., M.P.H. Department of Nephrology San Bortolo
More informationΟΙ ΒΙΟΔΕΙΚΤΕΣ ΚΑΡΔΙΟΛΟΓΙΑ ΣΗΜΕΡΑ ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ. Καθηγητής Καρδιολογίας
ΕΘΝΙΚΟ ΚΑΙ ΚΑΠΟΔΙΣΤΡΙΑΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΑΘΗΝΩΝ ΙΑΤΡΙΚΗ ΣΧΟΛΗ Ά ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ Διευθυντής: Καθηγητής Δημήτριος ΤΟΥΣΟΥΛΗΣ ΟΙ ΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΟΛΟΓΙΑ ΣΗΜΕΡΑ ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας
More informationST2 in Heart Failure. ST2 as a Cardiovascular Biomarker. Competitive Model of ST2/IL-33 Signaling. ST2 and IL-33: Cardioprotective
ST2 as a Cardiovascular Biomarker Lori B. Daniels, MD, MAS, FACC Professor of Medicine Director, Coronary Care Unit University of California, San Diego ST2 and IL-33: Cardioprotective ST2: member of the
More informationDoes serial troponin measurement help identify acute ischemia/ischemic events?
Does serial troponin measurement help identify acute ischemia/ischemic events? Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine and Laboratory Medicine & Pathology
More informationUndetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction
Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction Nadia Bandstein, MD; Rickard Ljung, MD, PhD; Magnus Johansson, MD, PhD; Martin Holzmann,
More informationAbout OMICS International
About OMICS International OMICS International through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community. OMICS International hosts over 700
More informationSpeaker: Richard Heitsman, MICT, C-POC-AACC. Title: National Account Manager/Clinical Cardiac Specialist-Radiometer America.
Speaker: Richard Heitsman, MICT, C-POC-AACC Title: National Account Manager/Clinical Cardiac Specialist-Radiometer America. Upon completion the participant will be able to o Review current and evolving
More informationClassification of lab tests useful in cardiac disease Biochemical markers in Acute Coronary Syndromes (ACS) Redefinition of Myocardial Infarction (MI)
Biochemical Markers in Cardiac Injury Dr Sami Saeed Assistant Professor/Consultant Chemical Pathologist Foundation University Medical College Fauji Foundation Hospital Rawalpindi Email: drsami@comsats.net.pk
More informationAssays Pros and Cons AACB 2013 GOLD COAST QUEENSLAND AUSTRALIA
Highly Sensitive Versus Sensitive Troponin Assays Pros and Cons AACB 2013 GOLD COAST QUEENSLAND AUSTRALIA Robert H. Christenson, Ph.D., DABCC, FACB 2013 AACC President Professor of Pathology Professor
More informationRapid exclusion of acute myocardial infarction in patients with undetectable troponin using a sensitive troponin I assay
Original Article Annals of Clinical Biochemistry 2015, Vol. 52(5) 543 549! The Author(s) 2015 Reprints and permissions: sagepub.co.uk/journalspermissions.nav DOI: 10.1177/0004563215576976 acb.sagepub.com
More informationCongreso Nacional del Laboratorio Clínico 2016
Can biomarkers help us make a better use of cardiac imaging for myocardial ischaemia rule-out in the Emergency Department? Alessandro Sionis Director Acute and Intensive Cardiac Care Unit Hospital de la
More informationThe Clinical Laboratory Working with Physicians to Improve Patient Care
The Clinical Laboratory Working with Physicians to Improve Patient Care Michael A. Pesce, PhD Professor Emeritus Columbia University Medical Center Department of Pathology and Cell Biology Objectives Troponin
More informationConference Paper Small Changes in Cardiac Troponin Levels Are Common in Patients with Myocardial Infarction: Diagnostic Implications
Conference Papers in Medicine, Article ID 583175, 5 pages http://dx.doi.org/10.1155/2013/583175 Conference Paper Small Changes in Cardiac Troponin Levels Are Common in Patients with Myocardial Infarction:
More informationEDUCATIONAL COMMENTARY UNDERSTANDING THE BENEFITS AND CHALLENGES OF HIGH- SENSITIVITY TROPONIN TESTING IN CLINICAL AND PATHOLOGY SETTINGS
SENSITIVITY TROPONIN TESTING IN CLINICAL AND PATHOLOGY SETTINGS Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE
More informationTopic. Updates on Definition of Myocardial Infarction
Topic Updates on Definition of Myocardial Infarction In the past, general consensus for MI? Definition of MI by WHO - Combination of 2 of 3 characteristics - 1. Typical Symptoms 2. Enzyme Rise 3. Typical
More informationDolore Toracico e Livelli di Troponina non Misurabili
Dolore Toracico e Livelli di Troponina non Misurabili Andrea Fabbri Dipartimento di Emergenza Presidio Ospedaliero Morgagni Pierantoni Azienda USL Romagna Forlì andrea.fabbri@auslromagna.it Rapid Exclusion
More informationBIOCHEMICAL EXAMINATION OF ACUTE MYOCARDIAL INFARCTION. Written by Lenka Fialová, translated by Jan Pláteník
BIOCHEMICAL EXAMINATION OF ACUTE MYOCARDIAL INFARCTION 1 Structure of heart muscle Written by Lenka Fialová, translated by Jan Pláteník Heart muscle (myocardium) is a particular form of striated muscle,
More informationPharmacologyonline 2: (2010) Newsletter Kakadiya and Shah
ROLE OF CREATINE KINASE MB AND LACTATE DEHYDROGENASE IN CARDIAC FUNCTION A REVIEW Jagdish Kakadiya*, Nehal Shah Department of Pharmacology, Dharmaj Degree Pharmacy College, Petlad- Khambhat Road, Dharmaj,
More informationMyocardial Infarction In Dr.Yahya Kiwan
Myocardial Infarction In 2007 Dr.Yahya Kiwan New Definition Of Acute Myocardial Infarction The term of myocardial infarction should be used when there is evidence of myocardial necrosis in a clinical setting
More informationCopeptin in heart failure: Associations with clinical characteristics and prognosis
Copeptin in heart failure: Associations with clinical characteristics and prognosis D. Berliner, N. Deubner, W. Fenske, S. Brenner, G. Güder, B. Allolio, R. Jahns, G. Ertl, CE. Angermann, S. Störk for
More informationImproving Diagnostic, Prognostic & Therapeutic Biomarkers in Heart Disease. Professor Mark Richards Medicine, University of Otago, Christchurch
Improving Diagnostic, Prognostic & Therapeutic Biomarkers in Heart Disease Professor Mark Richards Medicine, University of Otago, Christchurch BNP / NT-ProBNP H 2 N 1 Pro-BNP Cardiomyocyte 76 77 108 COOH
More informationEffective Health Care Program
Comparative Effectiveness Review Number 135 Effective Health Care Program Cardiac Troponins Used as Diagnostic and Prognostic Tests in Patients With Kidney Disease Executive Summary Background Cardiac
More informationACCESS hstni SCIENTIFIC LITERATURE
ACCESS hstni SCIENTIFIC LITERATURE 2017 2018 Table of contents Performance Evaluation of Access hstni A critical evaluation of the Beckman Coulter Access hstni: Analytical performance, reference interval
More informationLong-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease
Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease D. Dallmeier 1, D. Rothenbacher 2, W. Koenig 1, H. Brenner
More informationAcute Coronary Syndromes
High-sensitivity Troponins Difficult Friends in Acute Coronary Syndromes Roland Klingenberg, Christian M Matter, 2 Christophe Wyss, Danielle Hof, Arnold von Eckardstein and Thomas F Lüscher 6. Clinical
More informationPeri-operative Troponin Measurements - Pathophysiology and Prognosis
Peri-operative Troponin Measurements - Pathophysiology and Prognosis Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory
More informationA New Generation of Biomarkers Tests of Myocardial Necrosis: The Real Quality a Physician can get from the Laboratory
e-issn 1643-3750 DOI: 10.12659/MSM.892033 Received: 2014.07.18 Accepted: 2014.08.14 Published: 2015.01.28 A New Generation of Biomarkers Tests of Myocardial Necrosis: The Real Quality a Physician can get
More informationcobas h 232 system When on the spot cardiac decisions need on the spot results in Primary Care cobas cardio
cobas h 232 system When on the spot cardiac decisions need on the spot results in Primary Care Is there a better pathway? Without Point of Care (POC) testing Patient presents Blood sample taken Lab collects
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Clinical perspective It was recently discovered that small RNAs, called micrornas, circulate freely and stably in human plasma. This finding has sparked interest in the potential
More informationTROPONIN POSITIVE 2/20/2015 WHAT DOES IT MEAN? When should a troponin level be obtained?
TROPONIN POSITIVE WHAT DOES IT MEAN? Frequently Asked Questions Regarding the Use of Troponin in the Clinical Setting What does an elevated troponin level mean? Elevated troponin is a sensitive and specific
More informationThe Clinical Value of Cardiac Biomarkers in the Management of Acute Coronary Syndrome And Heart Failure
Monet N. Sayegh, MD Physician Consultant The Clinical Value of Cardiac Biomarkers in the Management of Acute Coronary Syndrome And Heart Failure Unrestricted Siemens Medical Solutions USA, Inc., 2016 Incidence
More informationBiomarkers in Heart Disease. Felix J. Rogers, DO, FACOI April 29, 2018
Biomarkers in Heart Disease Felix J. Rogers, DO, FACOI April 29, 2018 Biomarkers NIH: A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes,
More informationThe clinical value of natriuretic peptide testing in heart failure
The clinical value of natriuretic peptide testing in heart failure James L. Januzzi, Jr, MD, FACC, FESC Associate Professor of Medicine Harvard Medical School Roman W. DeSanctis Endowed Clinical Scholar
More informationImplementation and outcomes of point-ofcare testing in the emergency department of a large urban academic medical center
Implementation and outcomes of point-ofcare testing in the emergency department of a large urban academic medical center Kent Lewandrowski, MD Associate Chief Of Pathology, Massachusetts General Hospital
More informationBiomarkers in and of Critical Illness: What do they mean and are they useful? Rand Butcher CNC Intensive Care & Coronary Care The Tweed Hospital
Biomarkers in and of Critical Illness: What do they mean and are they useful? Rand Butcher CNC Intensive Care & Coronary Care The Tweed Hospital Northern NSW Local Health District Definition i i of a Biomarker
More informationEarly risk stratification is essential in the management of
Cystatin C A Novel Predictor of Outcome in Suspected or Confirmed Non ST-Elevation Acute Coronary Syndrome Tomas Jernberg, MD, PhD; Bertil Lindahl, MD, PhD; Stefan James, MD, PhD; Anders Larsson, MD, PhD;
More informationDocument Version Publisher s PDF, also known as Version of Record (includes final page, issue and volume numbers)
Variation of cardiac troponin I and T measured with sensitive assays in emergency department patients with noncardiac chest pain Scharnhorst, V.; Krasznai, K.; van 't Veer, M.; Michels, R.H. Published
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationΟξεία καρδιακή ανεπάρκεια: Ποιες παράμετροι συμβάλλουν στη διαστρωμάτωση κινδύνου των ασθενών;
Οξεία καρδιακή ανεπάρκεια: Ποιες παράμετροι συμβάλλουν στη διαστρωμάτωση κινδύνου των ασθενών; Γ. Φιλιππάτος, MD, FACC, FESC, FCCP Επ. Καθηγητής Καρδιολογίας Πανεπ. Αθηνών Clinical Outcomes in Patients
More informationDiagnostics guidance Published: 1 October 2014 nice.org.uk/guidance/dg15
Myocardial infarction (acute): Early rule out using high-sensitivity troponin tests (Elecsys Troponin T high-sensitive, e, ARCHITECT STAT T High Sensitive Troponin-I and AccuTnI+3 assays) Diagnostics guidance
More informationDiagnostics consultation document
National Institute for Health and Care Excellence Diagnostics consultation document Myocardial infarction (acute): Early rule out using high-sensitivity troponin tests (Elecsys Troponin T high-sensitive,
More informationInternational Journal of Cardiology and Cardiovascular Research Vol. 4(2), pp , September, ISSN:
International Journal of Cardiology and Cardiovascular Research Vol. 4(2), pp. 072-078, September, 2018. www.premierpublishers.org, ISSN: 3102-9869 IJCCR Research Article Copeptin as a Novel Biomarker
More informationProceedings of the 36th World Small Animal Veterinary Congress WSAVA
www.ivis.org Proceedings of the 36th World Small Animal Veterinary Congress WSAVA Oct. 14-17, 2011 Jeju, Korea Next Congress: Reprinted in IVIS with the permission of WSAVA http://www.ivis.org 14(Fri)
More informationPlasma MR-proADM is superior to NTproBNP for all-cause short term mortality prediction in acute pulmonary embolism.
J. Pedowska-Wloszek, M. Kostrubiec, A. Labyk, S. Pacho, O. Dzikowska-Diduch, P. Bienias, B. Lichodziejewska, P. Palczewski, M. Ciurzynski, P. Pruszczyk Plasma MR-proADM is superior to NTproBNP for all-cause
More informationRecent literature highlights the high negative
Cost-effectiveness and budget impact analysis of natriuretic peptide testing in the diagnosis of chronic heart failure Heart failure (HF) is a major reason for hospitalization and represents a huge cost
More informationA Guide to Proper Utilization of Biomarkers
A Guide to Proper Utilization of Biomarkers DR. ABEER BAKHSH CONSULTANT CARDIOLOGIST, ADVANCE HEART FAILURE KING FAHD ARMED FORCES HOSPITAL JEDDAH, SAUDI ARABIA Objective: Mechanism of myocardial injury
More informationAcute heart failure syndromes: clinical challenges. Pathophysiology. ESC Congress August. Paris, France. Marco Metra
ESC Congress 2011 27-31 August. Paris, France. Acute heart failure syndromes: clinical challenges. Pathophysiology Marco Metra Cardiology, Dept. Of experimental and applied medicine. University of Brescia.
More informationThe clinical performance of the novel POC Minicare ctni-assay. Per Venge, MD PhD Professor in Clinical Chemistry Uppsala University Uppsala, Sweden
The clinical performance of the novel POC Minicare ctni-assay Per Venge, MD PhD Professor in Clinical Chemistry Uppsala University Uppsala, Sweden Disclosure: Per Venge has received consultancy honoraria
More informationDECLARATION OF CONFLICT OF INTEREST. None
DECLARATION OF CONFLICT OF INTEREST None Controversies on marathon and beyond: Elevated biomarkers as a proof of cardiac damage: Contra Jürgen Scharhag, FACSM, FESC Internal Medicine III: Cardiology, Angiology
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationBNP as a Predictor of Cardiovascular Disease and All Cause Mortality. Dr. Thierry Le Jemtel
BNP as a Predictor of Cardiovascular Disease and All Cause Mortality Dr. Thierry Le Jemtel Outline Role of BNP and probnp as relevant biomarkers in cardiac conditions Role of BNP and probnp as relevant
More informationL utilizzo della Procalcitonina in Medicina d Urgenza
L utilizzo della Procalcitonina in Medicina d Urgenza Stefania Battista Dirigente Medico S.C. Medicina d Urgenza Azienda Ospedaliero-Universitaria San Giovanni Battista di Torino Savona, 15 ottobre 2009
More informationOverview & Update on the Utilization of the Natriuretic Peptides in Heart Failure
June 28, 2016 Overview & Update on the Utilization of the Natriuretic Peptides in Heart Failure Linda C. Rogers, PhD, DABCC, FACB. Agenda Overview of the Natriuretic Peptides and Efficacy studies Similarities
More informationRuolo dei Marcatori Bioumorali nello scompenso cardiaco
Ruolo dei Marcatori Bioumorali nello scompenso cardiaco Head Emergency Medicine Sant Andrea Hospital Director Postgraduate School of Emergency Medicine Faculty od Medicine and Psycology Sapienza University
More informationNon-commercial use only
Emergency Care Journal 2019; volume 15:7798 Determinants of troponin T and I elevation in old patients without acute coronary syndrome Antonio Di Micoli, 1 Chiara Scarciello, 1 Stefania De Notariis, 1
More informationA. BISOC 1,2 A.M. PASCU 1 M. RĂDOI 1,2
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 5 (54) No. 2-2012 THE ctntg4 PLASMA LEVELS IN RELATION TO ELECTROCARDIOGRAPHIC AND ECHOCARDIOGRAPHIC ABNORMALITIES IN
More informationQuantitative Measurement of Emergency Biomarkers in Parallel
Point-of-Care Immunoassay Analyzer Quantitative Measurement of Emergency Biomarkers in Parallel Troponin I, Myoglobin, CK-MB, D-Dimer, NTproBNP, hscrp Results in 17 minutes Direct measurement from whole
More informationRisk Stratification of ACS Patients. Frans Van de Werf, MD, PhD University of Leuven, Belgium
Risk Stratification of ACS Patients Frans Van de Werf, MD, PhD University of Leuven, Belgium Which type of ACS patients are we talking about to day? 4/14/2011 STEMI and NSTEMI in the NRMI registry from
More informationBIOCHEMICAL INVESTIGATIONS IN THE DIAGNOSTICS OF CARDIOVASCULAR DISORDERS. As. MARUSHCHAK M.I.
BIOCHEMICAL INVESTIGATIONS IN THE DIAGNOSTICS OF CARDIOVASCULAR DISORDERS As. MARUSHCHAK M.I. Heart attack symptoms Acute MI Measurement of cardiac enzyme levels Measure cardiac enzyme levels at regular
More informationDiagnostic and prognostic significance of high sensitive troponin in chest pain
European Review for Medical and Pharmacological Sciences Diagnostic and prognostic significance of high sensitive troponin in chest pain I. CASAGRANDA, E.C. LAURITANO Emergency Department, SS. Antonio
More information